Correspondence 0001493152-25-006747 from Basel Medical Group Ltd (BMGL)
Basel Medical Group Ltd
Date: Feb. 14, 2025 · CIK: 0002004489 · Accession: 0001493152-25-006747
AI Filing Summary & Sentiment
File numbers found in text: 333-282096
Letter
VIA EDGAR
February 14, 2025
U.S. Securities and Exchange Commission
Division of Corporation Finance
F. Street, NE
Washington, D.C. 20549
Attn: Nudrat Salik
Michael Fay
Robert Augustin
Jane Park
Re: Basel Medical Group Ltd
Registration Statement on Form F-1, as amended (File No. 333-282096)
Request For Acceleration of Effectiveness
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), Cathay Securities, Inc., acting as representative of the underwriters, hereby joins Basel Medical Group Ltd in requesting acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m., Eastern Time, on February 18, 2025, or as soon thereafter as practicable.
Pursuant to Rule 460 under the Securities Act, we wish to advise you that we have distributed as many copies of the preliminary prospectus dated February 13, 2025, to selected dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary Prospectus.
The undersigned confirm that it has complied and will continue to comply with, and it has been informed or will be informed by participating dealers that it has complied or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.
Very
truly yours,
Cathay
Securities, Inc.
Show Raw Text
CORRESP
1
filename1.htm
VIA
EDGAR
February
14, 2025
U.S.
Securities and Exchange Commission
Division
of Corporation Finance
100
F. Street, NE
Washington,
D.C. 20549
Attn:
Nudrat Salik
Michael
Fay
Robert
Augustin
Jane
Park
Re:
Basel Medical Group Ltd
Registration
Statement on Form F-1, as amended (File No. 333-282096)
Request
For Acceleration of Effectiveness
Ladies
and Gentlemen:
Pursuant
to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as
amended (the “Securities Act”), Cathay Securities, Inc., acting as representative of the underwriters, hereby joins Basel
Medical Group Ltd in requesting acceleration of the effective date of the above-referenced Registration Statement so that it will become
effective at 4:00 p.m., Eastern Time, on February 18, 2025, or as soon thereafter as practicable.
Pursuant
to Rule 460 under the Securities Act, we wish to advise you that we have distributed as many copies of the preliminary prospectus dated
February 13, 2025, to selected dealers, institutions and others as appears to be reasonable to secure adequate distribution of the Preliminary
Prospectus.
The
undersigned confirm that it has complied and will continue to comply with, and it has been informed or will be informed by participating
dealers that it has complied or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection
with the above-referenced issue.
Very
truly yours,
Cathay
Securities, Inc.
By:
/s/
Shell Li
Name:
Shell
Li
Title:
Chief
Executive Officer & Head of Investment Banking